Praxis precision medicines, inc.PRAX.US Overview
PRAX Overall Performance
PRAX AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
PRAX Current Performance
-2.01%
Praxis precision medicines, inc.
2.17%
Avg of Sector
0.85%
S&P500
PRAX Key Information
PRAX Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
PRAX Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
PRAX Profile
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhibitor of T-type calcium channels, which is in Phase IIa clinical trial for the treatment of essential tremor. The company is also developing PRAX-562, a persistent sodium current blocker that is in Phase I clinical trial to treat severe pediatric epilepsy and adult cephalgia; PRAX-222, an antisense oligonucleotide (ASO) for patients with gain-of-function (GOF) SCN2A epilepsy; and KCNT1 program for the treatment of KCNT1 GOF epilepsy. It has a cooperation and license agreement with RogCon Inc.; a license agreement with Purdue Neuroscience Company; a research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.
Price of PRAX
PRAX FAQ
When is PRAX's latest earnings report released?
The most recent financial report for Praxis precision medicines, inc. (PRAX) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating PRAX's short-term business performance and financial health. For the latest updates on PRAX's earnings releases, visit this page regularly.
How is PRAX's revenue growth?
In the latest financial report, Praxis precision medicines, inc. (PRAX) announced revenue of 0, with a Year-Over-Year growth rate of -100%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much cash does PRAX have?
At the end of the period, Praxis precision medicines, inc. (PRAX) held Total Cash and Cash Equivalents of 157.42M, accounting for 0.35 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is PRAX's EPS continuing to grow?
According to the past four quarterly reports, Praxis precision medicines, inc. (PRAX)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -3.31. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of PRAX?
Praxis precision medicines, inc. (PRAX)'s Free Cash Flow (FCF) for the period is -54.73M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 100.65% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.